Details for New Drug Application (NDA): 201821

NDA 201821 describes CLINDAMYCIN PALMITATE HYDROCHLORIDE, which is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Heritage Pharms Inc, Padagis Us, and Rising, and is included in seven NDAs. It is available from eight suppliers. Additional details are available on the CLINDAMYCIN PALMITATE HYDROCHLORIDE profile page.

The generic ingredient in CLINDAMYCIN PALMITATE HYDROCHLORIDE is clindamycin palmitate hydrochloride. There are fifty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the clindamycin palmitate hydrochloride profile page.

Summary for 201821

Tradename:	CLINDAMYCIN PALMITATE HYDROCHLORIDE
Applicant:	Rising
Ingredient:	clindamycin palmitate hydrochloride
Patents:	0

Pharmacology for NDA: 201821

Physiological Effect

Decreased Sebaceous Gland Activity Neuromuscular Blockade

Suppliers and Packaging for NDA: 201821

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CLINDAMYCIN PALMITATE HYDROCHLORIDE	clindamycin palmitate hydrochloride	FOR SOLUTION;ORAL	201821	ANDA	Bryant Ranch Prepack	63629-2391	63629-2391-1	100 mL in 1 BOTTLE (63629-2391-1)
CLINDAMYCIN PALMITATE HYDROCHLORIDE	clindamycin palmitate hydrochloride	FOR SOLUTION;ORAL	201821	ANDA	Rising Pharma Holdings, Inc.	64980-511	64980-511-10	100 mL in 1 BOTTLE (64980-511-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	FOR SOLUTION;ORAL			Strength	EQ 75MG BASE/5ML
Approval Date:	Aug 28, 2012	TE:	AA	RLD:	No

Complete Access Available with Subscription